奈米抗体市场－全球产业规模、份额、趋势、机会和预测，按类型、应用、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球奈米抗体市场规模为5.784亿美元，预计到2030年将以18.30%的复合年增长率增长至15.8539亿美元。奈米抗体，又称单域抗体，是源自骆驼科动物的紧凑型抗体片段，具有体积小、稳定性高和抗原亲和力高等特性。这些特性使其在治疗、诊断和研究应用方面具有重要价值。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球奈米抗体市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型（单一特异性、多特异性）
  • 依应用领域（后天性血栓性血小板减少性紫斑症 (TTP)、呼吸道合胞病毒感染、类风湿性关节炎、系统性红斑狼疮、肿瘤、干癣、慢性肾臟病、骨骼疾病、其他）
  • 按最终用户（製药和生物技术公司、研究实验室、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美奈米抗体市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲奈米抗体市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太奈米抗体市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲奈米抗体市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲奈米抗体市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球奈米抗体市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Hybrigenics Services
• Novo Nordisk A/S
• Merck KGaA
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Sanofi SA
• Beroni Group
• Shenzhen Kangti Co., Ltd.
• GlaxoSmithKline plc
• Sensei Biotherapeutics, Inc

第十六章：策略建议

第17章调查会社について・免责事项

The Global Nanobodies Market, valued at USD 578.4 Million in 2024, is projected to experience a CAGR of 18.30% to reach USD 1585.39 Million by 2030. Nanobodies, also known as single-domain antibodies, are compact antibody fragments derived from camelids, characterized by their small size, inherent stability, and high antigen affinity. These properties make them valuable for therapeutic, diagnostic, and research applications.

Key Market Drivers

The unique physicochemical properties of nanobodies constitute a primary driver for market expansion, owing to their compact size, inherent stability, and exceptional antigen-binding affinity. These attributes facilitate superior tissue penetration and the targeting of cryptic epitopes, often inaccessible to larger conventional antibodies, thus broadening their therapeutic utility. Nanobodies also exhibit lower immunogenicity, reducing the risk of adverse immune responses. The substantial potential of these characteristics attracts significant investment into companies leveraging nanobody platforms.

Key Market Challenges

The high cost associated with nanobody development and large-scale production represents a major barrier to the expansion of the global nanobodies market. These elevated expenses stem from the complex biotechnological processes, specialised expertise, and advanced infrastructure required throughout the discovery, development, and manufacturing stages. As a result, financial constraints limit the number of nanobody-based therapeutics and diagnostic products that successfully transition from research to commercialisation, thereby slowing overall market growth.

Key Market Trends

Advancements in nanobody production and bioprocessing technologies are significantly influencing the global market by enhancing scalability and reducing manufacturing complexities. The Parenteral Drug Association (PDA), at its 2024 Pharmaceutical Manufacturing & Quality Conference, extensively discussed the adoption of multiple advanced techniques, including flexible manufacturing, continuous manufacturing, and process analytical technology, to optimize bioprocessing efficiency. This focus underscores the industry's drive to streamline production and improve quality control.

Key Market Players

• Hybrigenics Services
• Novo Nordisk A/S
• Merck KGaA
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Sanofi S.A
• Beroni Group
• Shenzhen Kangti Co., Ltd.
• GlaxoSmithKline plc
• Sensei Biotherapeutics, Inc

Report Scope:

In this report, the Global Nanobodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanobodies Market, By Type:

• Mono-Specific
• Multi-Specific

Nanobodies Market, By Application:

• Acquired Thrombotic Thrombocytopenic Purpura (TTP)
• Respiratory Syncytial Virus Infection
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Oncology
• Psoriasis
• Chronic Kidney Diseases
• Bone Disorders
• Others

Nanobodies Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Research Laboratories
• Others

Nanobodies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nanobodies Market.

Available Customizations:

Global Nanobodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanobodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Mono-Specific, Multi-Specific)
  • 5.2.2. By Application (Acquired Thrombotic Thrombocytopenic Purpura (TTP), Respiratory Syncytial Virus Infection, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Oncology, Psoriasis, Chronic Kidney Diseases, Bone Disorders, Others)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Nanobodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nanobodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Nanobodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Nanobodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Nanobodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nanobodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Nanobodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Nanobodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Nanobodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Nanobodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Nanobodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nanobodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Nanobodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Nanobodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Nanobodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Nanobodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Nanobodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nanobodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Nanobodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Nanobodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Nanobodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nanobodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Nanobodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Nanobodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nanobodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Hybrigenics Services
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novo Nordisk A/S
• 15.3. Merck KGaA
• 15.4. Bristol Myers Squibb Company
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. Sanofi S.A
• 15.7. Beroni Group
• 15.8. Shenzhen Kangti Co., Ltd.
• 15.9. GlaxoSmithKline plc
• 15.10. Sensei Biotherapeutics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer